Stem cells, peptides, and whether the FDA is hiding anything

This episode takes up two product categories that are marketed on counts: stem cells by the million, peptides by the vial. Underneath the marketing sit three questions that decide whether either one is worth anything. How does the product actually work in the body? What do the sourcing rules in the United States allow, and why do patients fly to Tijuana or Panama for the rest? And for peptides, after fifty years, why is there still almost no human trial evidence? One of us recorded this episode the morning after a stem cell workshop, having arrived there a skeptic, which is where the stem cell half starts.

How stem cells actually work: signaling, not replacement

The picture sold to patients is that injected stem cells travel to damaged tissue and become new cartilage, new tendon, new organ. That is not the mechanism described by the people who work with these cells. The cells secrete exosomes, small vesicles carrying signaling molecules (the secretome), and those signals instruct the patient's own tissue to repair itself. The cell is a factory for signals. It is not a spare part.

This reframing matters for two reasons. It explains why the location of the injection matters less than patients assume, since the signals circulate. And it sets up the episode's central distinction: the value of a stem cell product is the quality and amount of signaling each cell produces, not the number of cells in the syringe.

The three sources, and what differs between them

Placental (birth tissue) cells. Mesenchymal stem cells sourced from full-term placentas of young donors. The claims made for them: young, naive cells with low antigenicity, meaning fewer of the surface markers that provoke an immune reaction, and no need to use the patient's own aged cells. Handling matters as much as source; the workshop's supplier used selective full-term placentas and slow cold storage rather than hard freezing, on the argument that freeze damage reduces the number of living, signaling cells delivered.

Your own bone marrow. Autologous cells, harvested and reinjected. No donor, no foreign DNA question, and a hard limit: a 65-year-old's cells are 65 years old, with the signaling capacity that comes with that.

Your own fat. Adipose tissue obtained by liposuction, minimally processed, reinjected. Same autologous trade-off as marrow, easier harvest.

Quality over quantity

Overseas clinics market cell counts: five hundred thousand cells, a million, thirty million. Expansion in culture is how those counts are reached. Cells are grown in a medium and double repeatedly until the number looks impressive. The counterclaim from the workshop, and the point that changed the skeptic at our table: each expansion dilutes the signaling output per cell. A smaller number of potent cells can out-signal a larger number of expanded ones. Count is the easiest number to print on a brochure and close to the least informative number in the product.

What United States rules allow, and why patients still fly out

The regulatory line in the US is manipulation. Take a patient's own fat or bone marrow, process it minimally, and reinject it in the same procedure, and the FDA treats that as the practice of medicine. Take umbilical or placental cells, grow them in culture, and reinject them, and the product is now a biologic drug that needs FDA approval, which no such product has for these uses. That is the legal reason the expanded-cell treatments happen in Mexico, Panama, and Colombia.

The trade-off cuts both ways, and the episode argues it in both directions. The restriction blocks access to the young-cell products. It also means a US product is traceable and clean in a way an overseas vial is not, the same quality problem that runs through the gray peptide market.

Exosomes versus stem cells

If the exosomes are the working signal, a patient can ask why not inject exosomes alone and skip the cells. The difference is timing. Exosomes are the signal, ready on delivery. Stem cells are the factory that goes on producing the signal for weeks after the injection. An acute problem argues for the ready signal; a chronic one argues for the factory; cost argues against doing both. One regulatory fact from the episode: exosomes were offered in US offices, including ours, until the FDA removed them. They are unapproved biologics, and that status has not changed.

Who should do the injection

This was the episode's open disagreement, and it is worth stating as two premises rather than a verdict.

Premise one: a knee, hip, or shoulder injection under ultrasound guidance is a routine procedure, well inside the skills of the physicians at this table, and the doctor who already manages the patient's hormones, inflammation, and nutrition is better placed to judge whether the injection belongs in the plan than a clinic that performs stem cell injections all day and nothing else.

Premise two: the injection is the easy part. The diagnosis is not. An MRI report can name one injury and miss another, and injecting a joint that has not had a proper orthopedic evaluation risks treating the wrong problem with an expensive product.

Both premises can be true at once. The practical floor the episode lands on: a confirmed diagnosis first, by whoever is qualified to make it, and the whole-patient work done by the doctor who knows the patient.

What patients report, and the repeat-purchase test

Several of us have sent patients abroad, or watched them go on their own, at costs around twenty thousand dollars. The reported pattern is consistent enough to describe. The first months often hurt more than baseline, partly because the protocols forbid anti-inflammatory drugs afterward. Reported benefit, when it comes, arrives over the following three to nine months. And many patients do not go back for a second round, including patients for whom the cost is not a barrier.

Two readings of that pattern were argued. One: the product acts mainly as an expensive, long-lasting anti-inflammatory. It can reduce pain for a stretch of months. It does not rebuild a bone-on-bone joint or regrow a torn meniscus, and the expectation that it reverses aging is a misconception. Two: results depend heavily on the injury and on the quality of the product, and there are individual cases, including one at this table after PRP had failed on a partial tendon tear, where the improvement was large and durable. Neither reading is settled by the anecdotes available.

Is this a longevity treatment?

For a healthy patient in their 50s or 60s with diet, training, hormones, and supplements already handled, who asks what is next: no one at this table is ready to name stem cells as a standard answer. The workshop's own framing, converted to plain terms: a stem cell product delivers signals into whatever environment the body currently is. High inflammation, poor nutrition, and unmanaged hormones degrade the signal before it can do anything. The environment work is the larger half of the treatment, and it is the half this practice already does. Stem cells, if they belong anywhere, belong after it, for a selected patient, and not as a routine annual purchase.

Peptides: fragments, signals, and fifty years of thin evidence

Peptides are short fragments of proteins. They attach to receptors and signal the body to do something: release growth hormone, calm inflammation, heal tissue. Two corrections to the popular account came up repeatedly. The administered compounds are not, in general, natural substances circulating in your body in that form. BPC-157 is a fragment modeled on a protein found in gastric juice. TB-500 is a short fragment of thymosin beta-4, a 43-amino-acid protein. And the category is not new: these compounds have been described since the 1970s, and physicians at this table have prescribed some of them for ten to fifteen years, with the shared assessment that a few have narrow uses, a small anti-inflammatory effect on a tendinopathy being the example given, and that an oral anti-inflammatory can match that effect without an injection.

The October 2026 decision, stated precisely

In October 2026, the FDA signaled that it would not pursue 503A compounding pharmacies, or the physicians prescribing for them, over a short list of peptides, named on the show as BPC-157, TB-500, Epitalon, KPV, MOTS-c, and Semax. What that is: enforcement discretion. What it is not: a finding that any of these compounds is safe or effective, or an approval. One argument made for the move is harm reduction: the gray market was already supplying these compounds from unknown sources, and licensed pharmacies under supervision are a safer channel than the alternative.

Why there are no human trials

A search of the trial literature for these compounds turns up animal work, limited even there, and almost no human trials in five decades. Four explanations were argued, and they are not mutually exclusive.

The patent problem. A fragment of a protein the body already makes is hard to protect. Medroxyprogesterone exists because a company modified natural progesterone into something patentable, and the modification changed how the molecule behaves. Without exclusivity, no sponsor recovers the cost of a trial program.

The cost problem. A trial program capable of winning approval runs into the hundreds of millions of dollars. Recruitment, controls, and endpoints at statistical significance are the expensive parts, and someone has to expect a return.

The gray market problem. The compounds are already sold everywhere, which destroys the exclusivity a trial sponsor would be paying to create.

The verdict problem. The simpler explanation: compounds that worked clearly would have attracted the money by now. Bremelanotide (Vyleesi), a peptide approved for female arousal after failing several times on its way through the process, is the counterexample that proves a path exists when a company believes in an indication. The MOTS-c analog program that was modified into a drug candidate and stopped after early trials for lack of efficacy cuts the other way.

The money examples in the episode run in both directions. Guaifenesin was a fifty-cent generic for decades before a branded version (Mucinex) reached twenty dollars on the strength of an approved indication. Sildenafil was developed for pulmonary arterial hypertension and became Viagra when trial patients reported erections. Companies do find money in old molecules when the indication is real.

The immune tolerance problem

A protein fragment the body has not seen before can be read as friend or as foe. DSIP, a sleep peptide, is the standing example at this table: patients loved it for about four days, and then it stopped working, consistent with the immune system clearing the fragment. The further concern raised, and it is a concern rather than a finding: if the immune system learns to react to a fragment, it may react to the similar fragment the body produces itself. Cycling peptides rather than running them continuously is the cautious practice that follows from that concern.

Take-home

Stem cells: a signaling treatment with a plausible mechanism, mixed patient-reported results, and no settled place in longevity practice yet. Diagnosis first, environment first, and homework before any clinic, domestic or overseas, with price as a quality signal rather than a discount to chase.

Peptides: a handful of compounds with narrow plausible uses, no human trial base, a regulatory green light that means only that enforcement is paused, and an open argument about whether the missing trials reflect patent economics or missing efficacy. Neither question got settled in this episode, and we left them that way on purpose.

Timestamps

• 00:00 Intro from a bed and breakfast in Franklin, Tennessee
• 03:26 The stem cell workshop: what changed a skeptic's mind
• 05:28 Should we be doing the injections ourselves?
• 06:27 Sourcing: placenta, bone marrow, fat, and what the FDA allows
• 09:11 Exosomes explained
• 12:40 Why patients go to Mexico and Panama
• 16:32 Exosomes vs. stem cells: which, and when
• 18:18 Mixed results, and why patients don't go back
• 21:27 Healing is signaling
• 23:38 Quality over quantity, and clean up the pool first
• 26:07 Is it a longevity treatment at all?
• 27:30 The disagreement, round two
• 31:46 Conspiracy corner: peptides and the FDA
• 33:44 Why pharma hasn't patented them
• 38:53 Where are the human trials?
• 41:18 What a drug trial costs
• 44:20 Guaifenesin, Viagra, and the money
• 47:18 Why the FDA may have loosened up
• 52:06 Take-home: stem cells in practice

Mentioned

• The Next 100 Years by Jeff Lauden (as cited on the show; title and spelling unverified)
• Bremelanotide (Vyleesi)
• Semax and Cerebrolysin, approved in Russia but not the US